Invention Grant
- Patent Title: Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
-
Application No.: US16268857Application Date: 2019-02-06
-
Publication No.: US10426135B2Publication Date: 2019-10-01
- Inventor: Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent James T. Wasicak
- Main IPC: C07D401/02
- IPC: C07D401/02 ; C07D401/10 ; A61K31/437 ; A61K31/4353 ; A01K5/01 ; B65D77/20 ; B65D25/04 ; B65D1/34 ; A01K7/00 ; A23K20/00 ; A23K50/48 ; B65D1/36 ; B65D25/18 ; B65D85/00
Abstract:
The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
Public/Granted literature
- US20190150401A1 Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof Public/Granted day:2019-05-23
Information query
